COMPANY PROFILE Company Details Genta Inc. The Group's principal activity is to develop a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Group's research platform is: DNA/RNA-based Medicines and Small Molecules. Genasense (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA ... More Genta Inc. The Group's principal activity is to develop a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Group's research platform is: DNA/RNA-based Medicines and Small Molecules. Genasense (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The main drug in Genta's Small Molecule program is Ganite (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypocalcaemia that is resistant to hydration. It has developed G4544, an oral formulation of the active ingredient in Ganite that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States
News 
Market Data 
Discover 
AI
